Pinz Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Pinz Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-51,240	Closed	-$669K	–	115
2022 Q2	$669K	Buy	+51,240	New	+$523K	0.46%	69
2021 Q3	–	Sell	-6,000	Closed	-$115K	–	185
2021 Q2	$115K	Buy	+6,000	New	+$116K	0.03%	192

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CCM

Conway Capital Management Burbank, California $214M AUM 22.99% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Pinz Capital Management's CLPT Position: Q3 2022 in Review

Pinz Capital Management sold out of ClearPoint Neuro (CLPT) in Q3 2022, closing a stake of 51,240 shares — an estimated $669K sold.

Pinz Capital Management first reported a position in CLPT in Q2 2021 and held it in 2 quarters. The position peaked at $669K in Q2 2022. 56 funds tracked by Wall St. Rank hold CLPT as of Q3 2022.

Pinz Capital Management reported no remaining ClearPoint Neuro position as of Q3 2022 after selling out during the quarter.
Pinz Capital Management sold 51,240 ClearPoint Neuro shares in Q3 2022, an estimated $669K.
Pinz Capital Management first reported a position in ClearPoint Neuro in Q2 2021 and held it in 2 quarters.
Pinz Capital Management's ClearPoint Neuro position peaked at $669K in Q2 2022.
56 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.